EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Impact of Dyslipidemia on Allogeneic Transplantation Outcomes and Cardiovascular Mortality in Patients with Acute Leukemias in the Post-Transplant Cyclophosphamide Era

Sema Seçilmiş iD, Burcu Aslan Candır iD, Uğur Hatipoğlu, Mert Seyhan iD, Bahar Uncu Ulu, Tuğçe Nur Yiğenoğlu, Dicle İskender, Merih Kızıl Çakar, Turgay Ulaş iD, Mehmet Sinan Dal, Fevzi Altuntaş

Pharmaceuticals · 25.03.2026 · 19 (4) · 529

DOI: 10.3390/ph19040529 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 25.03.2026. Verfasst von Sema Seçilmiş und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Bone Marrow Transplantation Center, Etlik City Hospital, Ankara 06170, Türkiye. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Allogeneic hematopoietic stem cell transplantation is associated with increased cardiovascular risk driven by endothelial dysfunction, chronic inflammation, and treatment-related metabolic disturbances, including dyslipidemia. In the contemporary era of post-transplant cyclophosphamide-based prophylaxis, the prognostic significance of dyslipidemia—particularly as assessed by non-HDL cholesterol—remains unclear. In this study, we aimed to compare the engraftment days, graft-versus-host disease (GVHD) development, relapse, overall survival rates, and cardiovascular mortality in patients using myeloablative/reduced intensity conditioning regimens with post-transplant cyclophosphamide (PTCy) 50 mg/kg/day for 2 days in patients with acute leukemias.

Methods

A total of 95 adult patients with acute leukemias were included in their first remission who underwent matched sibling donor transplantation with PTCy (50 mg/kg on days +3 and +4). Patients were stratified according to pre-transplant non-HDL-C levels ( 0.05); cumulative incidences of grade II–IV aGVHD at +100 days, grade III–IV aGVHD at +100 days, and moderate-severe cGVHD at 1 year, relapse-free survival, and non-relapse mortality at 1 year were comparable in two cohorts (all p > 0.05). GVHD-free/relapse-free survival (GRFS) at 1 year was also comparable across groups (p = 0.15). Median GRFS was 150 (95% CI: 120–330) days and 270 (95% CI: 154-not reached) days, respectively [HR was 0.68 (0.40–1.15), p = 0.15; GRFS at 1 year was 66.6% vs. 52.0%, respectively]. The groups were also comparable in terms of overall survival (OS). Follow-up ranged from 0.5 to 108 months, and median follow-up was 60 months in two cohorts. Median OS was not reached in non-HDL-C < 160 (95% CI: 70 months–not reached) and 67 months in non-HDL-C ≥ 160 groups (95% CI: 13 months–not reached) (Log rank = 0.21). No cardiovascular death events occurred during the follow-up period.

Conclusions

In this homogeneous matched sibling donor transplant cohort with extended follow-up and uniform administration of post-transplant cyclophosphamide, cyclosporine-based GVHD prophylaxis, and anti-thymocyte lymphoglobulin (ATLG), pre-existing dyslipidemia was not associated with an adverse impact on GRFS, NRM, PFS, CMV reactivation, OS or long-term cardiovascular mortality.

Schlagwörter

Stichwörter der Autor:innen

acute leukemiascardiovascular mortalitydyslipdemiahematopoietic stem cell transplantationpost-transplant cyclophosphamide

Autor:innen und Institutionen

  • Department of Hematology and Bone Marrow Transplantation Center, Etlik City Hospital, Ankara 06170, Türkiye.
  • Department of Hematology and Bone Marrow Transplantation Center, University of Health Sciences, Ankara Oncology Training and Research Hospital, Ankara 06200, Türkiye.
  • Department of Internal Medicine, Division of Hematology, School of Medicine, Ankara Yıldırım Beyazıt University, Ankara 06760, Türkiye.

ORCID-Profile: Sema Seçilmiş, Burcu Aslan Candır, Mert Seyhan, Turgay Ulaş

Zitieren

APA

Seçilmiş, S., Aslan Candır, B., Hatipoğlu, U., Seyhan, M., Uncu Ulu, B., Yiğenoğlu, T. N., İskender, D., Kızıl Çakar, M., Ulaş, T., Dal, M. S., & Altuntaş, F. (2026). Impact of Dyslipidemia on Allogeneic Transplantation Outcomes and Cardiovascular Mortality in Patients with Acute Leukemias in the Post-Transplant Cyclophosphamide Era. Pharmaceuticals, 19(4), 529. https://doi.org/10.3390/ph19040529

Vancouver

Seçilmiş S, Aslan Candır B, Hatipoğlu U, Seyhan M, Uncu Ulu B, Yiğenoğlu TN, et al. Impact of Dyslipidemia on Allogeneic Transplantation Outcomes and Cardiovascular Mortality in Patients with Acute Leukemias in the Post-Transplant Cyclophosphamide Era. Pharmaceuticals. 2026;19(4):529. doi:10.3390/ph19040529

BibTeX
@article{Seilmi2026,
  author = {Seçilmiş, Sema and Aslan Candır, Burcu and Hatipoğlu, Uğur and Seyhan, Mert and Uncu Ulu, Bahar and Yiğenoğlu, Tuğçe Nur and İskender, Dicle and Kızıl Çakar, Merih and Ulaş, Turgay and Dal, Mehmet Sinan and Altuntaş, Fevzi},
  title = {Impact of Dyslipidemia on Allogeneic Transplantation Outcomes and Cardiovascular Mortality in Patients with Acute Leukemias in the Post-Transplant Cyclophosphamide Era},
  journal = {Pharmaceuticals},
  year = {2026},
  volume = {19},
  number = {4},
  pages = {529},
  doi = {10.3390/ph19040529}
}
Kostenlos starten →